These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 23788085

  • 1. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.
    Kuliczkowski W, Urbaniak J, Hallén J, Woźniak M, Poloński L, Mysiak A, Atar D, Zembala M, Serebruany V.
    Kardiol Pol; 2013; 71(5):453-63. PubMed ID: 23788085
    [Abstract] [Full Text] [Related]

  • 2. Early measurements of plasma matrix metalloproteinase-2 predict infarct size and ventricular dysfunction in ST-elevation myocardial infarction.
    Nilsson L, Hallén J, Atar D, Jonasson L, Swahn E.
    Heart; 2012 Jan; 98(1):31-6. PubMed ID: 21727201
    [Abstract] [Full Text] [Related]

  • 3. Clinical significance of matrix metalloproteinases activity in acute myocardial infarction.
    Papadopoulos DP, Moyssakis I, Makris TK, Poulakou M, Stavroulakis G, Perrea D, Votteas VE.
    Eur Cytokine Netw; 2005 Jun; 16(2):152-60. PubMed ID: 15941687
    [Abstract] [Full Text] [Related]

  • 4. Left anterior descending coronary artery flow after primary angioplasty in acute anterior ST-elevation myocardial infarction: how much flow is needed for left ventricular functional recovery?
    Sharif D, Sharif-Rasslan A, Khalil A, Rosenschein U.
    Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):223-8. PubMed ID: 24493865
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of invasive treatment and the occurrence of cardiac rupture in acute ST-elevation myocardial infarction.
    Ptaszyńska-Kopczyńska K, Sobolewska D, Kożuch M, Dobrzycki S, Sobkowicz B, Hirnle T, Musiał WJ, Kamiński KA.
    Kardiol Pol; 2011 Sep; 69(8):795-800. PubMed ID: 21850621
    [Abstract] [Full Text] [Related]

  • 6. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.
    Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
    [Abstract] [Full Text] [Related]

  • 7. Prospective randomised study to evaluate effectiveness of distal embolic protection compared to abciximab administration in reduction of microembolic complications of primary coronary angioplasty.
    Ochała A, Smolka G, Wojakowski W, Gabrylewicz B, Garbocz P, Tendera M.
    Kardiol Pol; 2007 Jun; 65(6):672-80; discussion 681-3. PubMed ID: 17629829
    [Abstract] [Full Text] [Related]

  • 8. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
    Hassan AK, Liem SS, van der Kley F, Bergheanu SC, Wolterbeek R, Bosch J, Bootsma M, Zeppenfeld K, van der Laarse A, Atsma DE, Jukema JW, Schalij MJ.
    Catheter Cardiovasc Interv; 2009 Aug 01; 74(2):335-43. PubMed ID: 19642182
    [Abstract] [Full Text] [Related]

  • 9. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
    Brunner S, Kim JO, Methe H.
    Am J Cardiol; 2010 Feb 15; 105(4):429-34. PubMed ID: 20152234
    [Abstract] [Full Text] [Related]

  • 10. [Evaluation of plasma renin activity in acute myocardial infarction patients treated with primary percutaneous coronary interventions].
    Stryjewski PJ, Pietrucha AZ, Stopyra K, Nessler B, Kruszelnicka O, Gackowski A, Konduracka E, Sztefko K, Badacz L, Nessler J.
    Przegl Lek; 2011 Feb 15; 68(7):354-8. PubMed ID: 22010471
    [Abstract] [Full Text] [Related]

  • 11. Expression of the tissue inhibitor of metalloproteinase-3 by transplanted VSMCs modifies heart structure and function after myocardial infarction.
    Jia ZB, Tian H, Kang K, Miao HZ, Liu KY, Jiang SL, Wang LP.
    Transpl Immunol; 2014 May 15; 30(4):149-58. PubMed ID: 24727088
    [Abstract] [Full Text] [Related]

  • 12. Effect of matrix metalloproteinase and their inhibitors on atrial myocardial structural remodeling.
    Wang W, Zhang HT, Yang XL.
    J Cardiovasc Med (Hagerstown); 2013 Apr 15; 14(4):265-9. PubMed ID: 22929563
    [Abstract] [Full Text] [Related]

  • 13. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.
    Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, Spinale FG.
    Circulation; 2006 Sep 05; 114(10):1020-7. PubMed ID: 16923753
    [Abstract] [Full Text] [Related]

  • 14. Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction.
    Yan HB, Li SY, Song L, Wang J, Wu Z, Chi YP, Zheng B, Zhao HJ, Li QX, Zhang XJ, Li WZ.
    Chin Med J (Engl); 2010 Apr 05; 123(7):877-83. PubMed ID: 20497681
    [Abstract] [Full Text] [Related]

  • 15. The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina.
    Furenes EB, Arnesen H, Solheim S, Grøgaard HK, Hoffmann P, Seljeflot I.
    Thromb Res; 2009 Nov 05; 124(5):560-4. PubMed ID: 19410278
    [Abstract] [Full Text] [Related]

  • 16. Usefulness of plasma matrix metalloproteinase-9 level in predicting future coronary revascularization in patients after acute myocardial infarction.
    Wang KF, Huang PH, Chiang CH, Hsu CY, Leu HB, Chen JW, Lin SJ.
    Coron Artery Dis; 2013 Jan 05; 24(1):23-8. PubMed ID: 23151854
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction.
    Zhang H, Tian NL, Hu ZY, Wang F, Chen L, Zhang YJ, Chen SL.
    Chin Med J (Engl); 2012 May 05; 125(10):1713-9. PubMed ID: 22800889
    [Abstract] [Full Text] [Related]

  • 19. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR.
    Circulation; 2006 May 02; 113(17):2089-96. PubMed ID: 16636176
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.